Oligomerix, a privately held company focused on the discovery and development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, has appointed James Hendrix, Ph.D., senior director of chemistry.
Hendrix has more than 20 years of pharmaceutical research experience, predominantly in neuroscience, including AD. His focus is on the discovery of drug candidates, having led teams that have advanced many compounds into clinical and preclinical development.
At Sanofi, he was director of medicinal chemistry with a focus on central nervous system (CNS) disorders. Hendrix managed 30 medicinal chemists focused on drug discovery for CNS targets and was a member of the company's global CNS management board.